Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression

ObjectiveTo explore the efficacy of c in the multiline treatment of late-stage lung adenocarcinoma with Her-2 overexpression and epidermal growth factor receptor (EGFR) mutations.MethodsWe summarize the diagnosis and treatment of a female patient with EGFR 21L858R mutation combined with Her-2 overex...

Descripció completa

Dades bibliogràfiques

Autors principals:	Meiling Lan, Tianyun Wang, Diexiao Luo, Yan Chen, Wei Liang, Rui Kong, Qichao Xie
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-12-01
Col·lecció:	Frontiers in Oncology
Matèries:	HER-2 overexpression epidermal growth factor receptor lung adenocarcinoma disitamab vedotin efficacy multiline treatment
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1472545/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!